MediciNova, Inc. — Q1 2023 Form 10-Q Summary
Business Context and Reporting Period
MediciNova is a biopharmaceutical company developing therapeutics for serious diseases with unmet medical needs. Its principal programs are MN-166 (ibudilast) for neurological, respiratory, addiction and other disorders, and MN-001 (tipelukast) for fibrotic diseases. The pipeline also includes MN-221 and MN-029. The filing covers the unaudited three months ended March 31, 2023, and was filed May 11, 2023.
Financial Performance and Position
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research, development and patents expense | $1.5 million | $2.1 million |
| General and administrative expense | $1.5 million | $1.3 million |
| Total operating expenses | $3.0 million | $3.4 million |
| Operating loss | $3.0 million | $3.4 million |
| Interest income | $0.5 million | $0.04 million |
| Other expense | $0.5 million | $0.01 million |
| Net loss | $2.9 million | $3.4 million |
| Basic and diluted loss per share | $0.06 | $0.07 |
| Net cash used in operating activities | $3.2 million | $3.7 million |
Cash and cash equivalents were $55.3 million at March 31, 2023, compared with $18.5 million at December 31, 2022. The increase primarily reflected $39.9 million of proceeds from the disposal of bank certificates of deposit. Total current assets were $56.0 million and working capital was $53.3 million. The company had no debt described as senior or other borrowing in the filing; total liabilities were $3.4 million, including $0.6 million of operating lease liabilities.
Total assets were $71.1 million and stockholders’ equity was $67.7 million at March 31, 2023. The accumulated deficit was $410.0 million. Stock-based compensation expense increased to $0.4 million from $0.1 million in the prior-year quarter.
Material Changes Versus the Prior Comparable Period
- Research and development expense declined by approximately $0.6 million, primarily because of lower MN-166-related manufacturing expense.
- General and administrative expense increased by approximately $0.2 million, primarily because of higher performance-based stock option expense.
- Interest income increased by approximately $0.5 million because of higher interest rates on cash and certificates of deposit.
- Other expense increased by approximately $0.5 million because of penalties incurred on early disposal of certificates of deposit.
- Operating cash use improved by approximately $0.6 million year over year.
- Cash increased substantially because the company liquidated certificates of deposit; this was a balance-sheet and investing activity change rather than operating revenue generation.
- No common stock was sold under the company’s $75.0 million at-the-market facility during either comparable quarter.
Guidance, Outlook, Risks and Unusual Items
Management expects research, development and patent costs to increase through the remainder of 2023 as development programs progress. The company expects substantial net losses for the next several years and does not currently generate meaningful operating revenue.
Management stated that available cash and working capital are sufficient to fund operations at least through the end of 2024, but cautioned that resources may not be sufficient to conduct all planned research and development programs. Additional financing, partnerships, grants or other non-dilutive funding may therefore be required.
Key development priorities include MN-166 and MN-001. The company reported positive top-line results in June 2022 from a Phase 2 MN-166 trial evaluating prevention of COVID-19-related acute respiratory distress syndrome. In February 2023, Health Canada authorized commencement of the grant-funded RECLAIM trial evaluating MN-166 and other therapies for Long COVID.
- Clinical development, enrollment, safety, efficacy and regulatory approval remain significant uncertainties.
- The company relies substantially on MN-166 and MN-001 and depends on third parties for clinical trials, manufacturing, licensing, marketing and distribution.
- COVID-19 or other health outbreaks may disrupt trial enrollment, operations, suppliers and workforce.
- Future potential milestone payments were approximately $10.0 million for MN-166 and MN-001 and $16.5 million for other products. Timing is uncertain and no milestone payments were made in the quarter.
- Operating lease commitments totaled $0.8 million in undiscounted minimum payments, with recorded lease liabilities of $0.6 million.
- The filing reports no material legal proceedings and no material changes to previously disclosed risk factors.
- Disclosure controls and procedures were assessed as effective at the reasonable assurance level, with no material change in internal control over financial reporting.
Investor Verification Checklist
- Verify the company’s cash runway assumptions and whether planned clinical activities can be funded through the end of 2024 without additional capital.
- Assess the timing, funding source and clinical progress of MN-166 and MN-001 programs, including RECLAIM.
- Review the impact of liquidating certificates of deposit, including the $0.1 million investment disposal loss and the sustainability of interest income.
- Monitor potential milestone obligations, licensing terms and any future royalty or partnership commitments.
- Track the planned increase in research and development spending and the company’s continuing operating losses.
- Evaluate dilution risk under the $75.0 million ATM facility and from approximately 8.7 million outstanding stock options.